Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT00835770 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00835770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00835770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
February 3, 2009
Completion date
November 8, 2019
Enrollment
1,736 (actual)
Sites
246

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis